The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. announced a worldwide exclusive license agreement and clinical trial agreement to develop and advance AmMax’s AMB-066 monoclonal antibody therapy as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease as well as those with MRD in other solid tumors.
Two studies led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center provide insight into how the immune system can successfully be activated against glioblastoma while revealing why these therapies have historically fallen short.
